NervGen Pharma Corp. @NervgenP Twitter profile

Last Seen Profiles

@l_2so

@DrekosRevenge

@bokeplokalmalam

@IucasIuvr

@SaudiEmp

@bokeplokalmalam

@revolutionawy

@BDesniar

@lu97857_

@LuxxArt

@Ringo_Toge_

@stwmaniax

@AgriPlantSoil

@PaimaModels

@BinorRaja

@4Sachey

@bokeplokalmalam

@6milepopstar

@ThymeOutGourmet

@McKeausel4ZsD9

@onlynahar

@MikeGrinnell_

@stwmaniax

@prime_skins

@bokeplokalmalam

@LacrimaBaccus

@bokeplokalmalam

@salamAJ5

@telugu

@shootsuave

@jandakembangstw

@FabienAudy

@gracereidmiller

@bokeplokalmalam

@senyurekbjk08

@bokeplokalmalam

NervGen Pharma Corp.

@NervgenP

3 years

@NervgenP drug NVG-291 could reverse the damage caused by Alzheimer’s reports @DailyMailUK #Alzheimers #neuroscience #Biotech

4

26

237

NervGen Pharma Corp.

@NervgenP

2 years

The origins of @NervgenP described as "a story of tragedy, a hope and a dream, and one for which the end is yet to be written" says @NervGenP founder in new book by @jancavelle

7

16

157

NervGen Pharma Corp.

@NervgenP

3 years

Check out @codi_darnell 's latest 'Nerve Matters' article about erasing the stigma on mobility aids with her interview with Tara Merrill, at: #NerveMatters #MultipleSclerosis @NervgenP

2

12

99

NervGen Pharma Corp.

@NervgenP

9 months

Our lead drug candidate, NVG-291, is a first-in-class therapeutic that has the potential to enable repair of the nervous system. It’s currently being evaluated in a Phase 1b/2a clinical trial for individuals with spinal cord injury. View our full video to learn more:

0

14

62

NervGen Pharma Corp.

@NervgenP

2 years

NVG-291-R, developed by @NervgenP is focus of new animal stroke study, conducted by @uofcincy and @cwru which showed improved memory, motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset. #ScienceTwitter

3

9

76

NervGen Pharma Corp.

@NervgenP

10 months

𝗥𝗲𝗺𝗮𝗿𝗸𝗮𝗯𝗹𝗲 𝗣𝗲𝗼𝗽𝗹𝗲's @GuyKawasaki , interviews @CWRU spinal cord injury researcher, 𝗗𝗿. 𝗝𝗲𝗿𝗿𝘆 𝗦𝗶𝗹𝘃𝗲𝗿, on his remarkable scientific journey. @CWRUSOM @MaverixPE @ruffoloj @AndrewBellBNN @AbilityLab @youngcodling @DougRoland @X

0

8

57

NervGen Pharma Corp.

@NervgenP

11 months

"In early clinical trials with a drug candidate that may repair damaged nerves in spinal cord injuries, @NervgenP receives FDA Fast Track designation," reports @BIVnews . #spinalcordinjury @AbilityLab @ruffoloj @MaverixPe

Vancouver spinal injury drug gets fast-tracked review

NervGen recently began early clinical trials of a drug candidate that may repair nerve damage

www.biv.com

0

16

68

NervGen Pharma Corp.

@NervgenP

10 months

Advances in modern medicine allow for things once never thought possible, like the repair of nervous system damage. Watch the full video to learn more about the potential of NVG-291. #biotech #neuroscience #innovation

0

12

67

NervGen Pharma Corp.

@NervgenP

8 months

NervGen Pharma Corp. is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of NVG-291 in individuals with spinal cord injury at the Shirley Ryan @AbilityLab in Chicago. Some of the eligibility requirements for this trial include: ▶ Age 18-75 ▶

0

16

66

NervGen Pharma Corp.

@NervgenP

9 months

We believe our lead drug candidate, NVG-291, has the potential to promote groundbreaking nervous system repair and functional recovery in #spinalcordinjuries , and possibly in other neurological diseases like #Stroke #Alzheimers or #MS . Watch the full video:

0

14

65

NervGen Pharma Corp.

@NervgenP

7 months

NervGen Pharma on track to complete enrollment, deliver data readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury:

NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial...

On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning...

www.newsfilecorp.com

0

20

66

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma Sets Sights on Trial for Spinal Cord Treatment reports @OutsourcedPharm #clinicaltrials #clinicalresearch

7

11

60

NervGen Pharma Corp.

@NervgenP

11 months

The @US_FDA has granted Fast Track designation for @NervGenP 's proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). Press release at: #spinalcordinjury #FDA @AbilityLab #Innovation

0

14

61

NervGen Pharma Corp.

@NervgenP

1 year

First subject dosed In @NervGenP 's Landmark Phase 1b/2a Clinical Trial for NVG-291 in spinal cord injury at @AbilityLab . Press release at: #clinicaltrials #clinicaltrial #spinalcordinjury

0

19

60

NervGen Pharma Corp.

@NervgenP

2 years

"...for everything from sun tanning and swimming to beach volleyball and sandcastle building. But for all the activities and fun beaches offer, they often lack one very important thing: accessibility." Read more in this week's blog post! #accessibility

Making Beaches More Accessible - NervGen Pharma

By Codi Darnell July 26, 2022 Nothing screams summer quite like a day at the beach. There are beaches covering thousands of miles of coastline around the world, and even more that surround the lakes...

nervgen.com

3

6

48

NervGen Pharma Corp.

@NervgenP

7 months

NervGen Pharma Corp. announces we've made the 2024 TSX #Venture50 list! The ranking by TSX Venture 50 recognizes the top 50 fastest growing companies on #TSXV in the past year. @NervgenP 's President & CEO, Mike Kelly, talks about the significance of this recognition and the

0

6

52

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma continues clinical trial of new Alzheimer's Drug via @clarksville_tn

NervGen Pharma continues clinical trial of new Alzheimer's Drug - Clarksville Online - Clarksville...

Vancouver, Canada - More than 6 million people in the United States live with Alzheimer’s, and that number continues to increase each year. In 2021,

www.clarksvilleonline.com

0

2

46

NervGen Pharma Corp.

@NervgenP

3 months

NervGen announced plans for developing a new drug candidate, NVG-300, adding diversity to its pipeline incl. new potential indications: ischemic stroke, ALS. Learn more about a new molecule that was discovered at NervGen: #announcement #stroke #ALS #SCI

7

15

50

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma announces completion of dosing of all subjects in Phase 1 clinical trial of proprietary drug candidate NVG-291. Click link below to read full press release! #clinicaltrial #research #drugdevelopment #biotech #spinalcordinjury #nervoussystem

7

9

45

NervGen Pharma Corp.

@NervgenP

2 years

NervGen recognizes March as Multiple Sclerosis Awareness month. Thank you to @MSNewsToday for reporting on our NVG-291 in healthy volunteers. #MultipleSclerosis

4

8

44

NervGen Pharma Corp.

@NervgenP

10 months

@NervgenP is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of NVG-291 in individuals with spinal cord injury at @AbilityLab in Chicago. Some of the eligibility requirements for this trial include: ▶ Age 18-75 ▶ Cervical SCI resulting from acute

0

14

46

NervGen Pharma Corp.

@NervgenP

9 months

In 2009, Dr. Jerry Silver began focusing on creating treatments that enhance the repair of the nervous system by preventing signals that inhibit the repair process. In 2015, NVG-291 was identified. Watch the full video: #spinalcordinjury #meded

0

10

45

NervGen Pharma Corp.

@NervgenP

1 month

#DYK Each year in the US approx. 18,000 spinal cord injuries are diagnosed. NervGen’s lead drug candidate, NVG-291, is currently in #clinicaltrials in our lead indication, #SCI .

4

8

45

NervGen Pharma Corp.

@NervgenP

2 years

In this week's blog post we hear about the "Dos and Don'ts" of listening to a podcast about your condition. Read more from Codi Darnell at link below! #blog #research #biotech #disability #podcast

Dos and Don’ts of Listening to Podcasts About Your Condition - NervGen Pharma

By Codi Darnell August 9, 2022 The podcast world has exploded. Whether it’s your next-door neighbour or your favourite celebrity, it suddenly feels as though everyone is streaming themselves onto the...

nervgen.com

5

6

41

NervGen Pharma Corp.

@NervgenP

10 months

Q3 2023 financial results and key updates from @NervgenP : 🌟 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞: Phase 1a/2b trial of NVG-291 is in full swing. 🚀 𝐅𝐃𝐀 𝐑𝐞𝐜𝐨𝐠𝐧𝐢𝐭𝐢𝐨𝐧: NVG-291 has been granted Fast Track designation by the U.S. FDA for spinal cord injury. 🔍

0

11

42

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma Receives FDA Authorization To Expand Enrollment Of Males And Premenopausal Females In Phase 1 Clinical Trial Of NervGen’s NVG-291! Read full press release at link below.

13

7

39

NervGen Pharma Corp.

@NervgenP

1 year

“NervGen made considerable progress in the quarter to advance our landmark Phase 1a/2b clinical study of NVG-291 for individuals with spinal cord injury,” said Mike Kelly, @NervgenP 's President & CEO. ↠ #spinalcord @AbilityLab

0

3

42

NervGen Pharma Corp.

@NervgenP

3 years

Learn how @NervgenP technology works to heal the nervous system in @YahooNews article at:

1

6

41

NervGen Pharma Corp.

@NervgenP

3 years

“NVG-291’s ability to remyelinate and enhance plasticity is a one-two knockout punch for repairing a faulty central nervous system,” says Paul Brennan, CEO of @NervgenP , a biotech company.

0

11

37

NervGen Pharma Corp.

@NervgenP

5 months

@NervgenP Reports 2023 Year-End Financial Results and Operational Updates: • Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 • CA$23 million bought deal financing completed in March 2024 provides expected cash runway

0

11

40

NervGen Pharma Corp.

@NervgenP

2 months

Our CONNECT SCI Study examines an investigational treatment, NVG-291, that has the potential to enable the nervous system to repair itself. Learn more about eligibility requirements and enrollment: #spinalcordinjury

1

9

39

NervGen Pharma Corp.

@NervgenP

1 year

"Road to Nervous System Repair Inspired by 20th Century Nobel Prize Winner," by @NervgenP 's co-founder Bill Radvak in @Tech_Networks . #spinalcordinjury #clinicalresearch #drugdevelopment #research #nobel

4

5

36

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma announces intent to conduct groundbreaking spinal cord injury clinical trial in exclusive partnership with @AbilityLab , #1 -Ranked Hospital in Physical Medicine & Rehabilitation. Read full press release below! #clinicaltrial #spinalcordinjury

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in...

NervGen Pharma announces it has entered into a Memorandum of Understanding with Shirley Ryan AbilityLab.

www.businesswire.com

0

7

40

NervGen Pharma Corp.

@NervgenP

1 year

@NervGenP 's landmark clinical trial for spinal cord injury to proceed at @AbilityLab 𝗥𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗶𝗻𝗱𝗶𝘃𝗶𝗱𝘂𝗮𝗹𝘀 𝘄𝗶𝘁𝗵 𝘀𝗽𝗶𝗻𝗮𝗹 𝗰𝗼𝗿𝗱 𝗶𝗻𝗷𝘂𝗿𝘆 (𝗦𝗖𝗜) 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱 #spinalcordinjury #ClinicalTrial

0

8

39

NervGen Pharma Corp.

@NervgenP

1 year

Dr. Jerry Silver's research focuses on the glial scar which forms at sites of a physical injury such as spinal cord injury, as well as sites of damage from diseases such as Alzheimer’s and multiple sclerosis. @cwru @Wingsforlife @abilitylab #clinicaltrials

0

6

40

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma's (TSX-V: NGEN, OTCQX: NGENF) President & CEO, Paul Brennan, on repairing the nervous system in interview with Torrey Hills Capital. NervGen’s drug, NVG-291, is moving rapidly towards Phase 1b/2 clinical trials for AD, SCI and MS.

5

3

37

NervGen Pharma Corp.

@NervgenP

2 months

. @KarenJagoda interviewed NervGen’s President & CEO, Mike Kelly, on the #EmpoweredPatient podcast about NervGen’s clinical program, and NVG-300, the new drug candidate announced earlier this week. Listen here:

2

10

39

NervGen Pharma Corp.

@NervgenP

4 months

NervGen today announced that it will be presenting two posters at the upcoming @ASIA_spine Annual Scientific Meeting, being held May 20-23, 2024. Read the full release here:

6

12

39

NervGen Pharma Corp.

@NervgenP

2 months

#NEWS : NBC Chicago featured our CONNECT SCI Study, , with @abilitylab , highlighting the importance of clinical research to find a potential new approach in #spinalcordinjury treatment. View NBC Chicago's segment:

Study determining whether investigational drug can aid those with spinal cord injuries underway

Scientists at the Shirley Ryan AbiilityLab in Chicago are studying whether an investigational drug can help the 300,000 Americans living with spinal cord injuries. NBC Chicago’s Lauren Petty reports.

www.nbcchicago.com

0

8

37

NervGen Pharma Corp.

@NervgenP

2 years

NervGen receives approval to proceed to the final dose cohort in Phase 1 clinical trial of NVG-291 and reports Q1 2022 results. Read full press release at link below -

8

10

36

NervGen Pharma Corp.

@NervgenP

1 year

NervGen will be presenting our Phase 1b/2a Study Design at the American Spinal Injury Association 50th Annual Scientific Meeting next week! Read full press release here - #conference #science #neuroscience #spinalcordinjury #research #clinicaltrial

6

33

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma and Big Business Show via @YouTube

NervGen Pharma and Big Business Show

Paul Brennan, President & CEO, NervGen Pharma, a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and dev...

www.youtube.com

2

6

31

NervGen Pharma Corp.

@NervgenP

1 year

Enabling the nervous system to repair itself @NervgenP @AbilityLab @WFLWorldRun #Spinalcordinjury #clinicaltrials #clinicalresearch

0

6

35

NervGen Pharma Corp.

@NervgenP

2 years

Dosing completed in 3rd Multiple Ascending Dose (MAD) cohort in Phase 1 Clinical Trial Of NVG-291 & Q3 '22 results in news release issued by @NervGenP today: #clinicaltrial #Biotechnology

6

5

35

NervGen Pharma Corp.

@NervgenP

28 days

Read this Q&A with NervGen’s President & CEO, Mike Kelly, and @Rob_TMM of the @medicine_maker to learn about NervGen’s lead drug, NVG-291, and the ongoing clinical trial for spinal cord injury. Read the full article: #SCI #SpinalCordInjury

0

9

36

NervGen Pharma Corp.

@NervgenP

2 months

A spinal cord injury occurs whenever there is damage to any part of the spinal cord. It can cause changes in feeling, movement, strength, and body functions below the site of injury. Learn more about our CONNECT SCI Study: #clinicaltrials

2

9

36

NervGen Pharma Corp.

@NervgenP

3 months

NervGen President & CEO, Mike Kelly, will be presenting a corporate update at the @SciSymposium on June 27, 2024, at 2 p.m. PDT during the Clinical Spinal Cord Injury Session. Advanced registration is required. Learn more: #SpinalCordInjury

5

6

35

NervGen Pharma Corp.

@NervgenP

2 months

NervGen’s President & CEO, Mike Kelly, spoke with @chrisleidli on the Rx for Biotech podcast about NervGen’s lead drug candidate, NVG-291, the company’s recent financial and operational milestones, and NervGen’s goals for the next few years.

2

8

34

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma Awarded Up To $1.5 Million US Department Of Defense Funding To Evaluate NervGen’s NVG-291-R For Peripheral Nerve Injury - click link to read full press release!

8

6

33

NervGen Pharma Corp.

@NervgenP

1 year

“ @nervgenp developed a unique trial design to evaluate NVG-291’s ability to restore function in humans with SCI," says Mike Kelly, CEO. Read more in press release: #Spinalcordinjury #clinicaltrial

21

2

30

NervGen Pharma Corp.

@NervgenP

3 months

The CONNECT SCI Study website, , for our Phase 1b/2a clinical trial in #spinalcordinjury is now live. The study involves NVG-291, an investigational treatment, that has the potential to enable the nervous system to repair itself. #clinicaltrials

5

8

32

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma receives approval from safety review committee to proceed to second cohort in multiple ascending dose portion of Phase 1 clinical trial of NVG-291! Read full press release at link below. #clinicaltrials #drugdevelopment #biotech #research

3

5

30

NervGen Pharma Corp.

@NervgenP

1 year

Wings for Life to support @NerGenP 's upcoming spinal cord injury clinical trial @AbilityLab with over US$3M. News release at: @redbull @AbilityLab #spinalcordinjury #clinicaltrials

0

4

29

NervGen Pharma Corp.

@NervgenP

2 months

Read about our plans to expand our pipeline of new molecules addressing high unmet need neurologic indications while remaining focused on our lead candidate, NVG-291, adding diversity to our pipeline and strategic partnering opportunities in @BioWorld .

2

6

30

NervGen Pharma Corp.

@NervgenP

2 years

Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Value. Read @NervgenP CEO, Paul Brennan's article in @GritDaily #Alzheimers #Biotechnology

3

4

28

NervGen Pharma Corp.

@NervgenP

12 days

NBC Chicago featured our CONNECT SCI Study, , with @abilitylab , highlighting the importance of clinical research to find a potential new approach in #SpinalCordInjury treatment. View NBC Chicago's segment

0

8

29

NervGen Pharma Corp.

@NervgenP

1 year

@NervGenP CEO, Mike Kelly, connects with @OutsourcPharma on 'hiring' for a peptide (NVG-291) that repairs nerve damage: #spinalcordinjury #spinalcordinjury

0

7

28

NervGen Pharma Corp.

@NervgenP

10 months

Interview with @NervgenP President & CEO, Mike Kelly, Co-founder, Dr. Harold Punnett and Co-Inventor & Scientific Advisor, Dr. Jerry Silver @ @briancrombie . @AbilityLab @MaverixPe @ruffoloj #clinicaltrials #spinalcordinjury

0

6

28

NervGen Pharma Corp.

@NervgenP

2 months

NervGen announces the appointment of Neil Klompas, experienced life sciences executive and board member, to the company’s Board of Directors. Read the full release here:

0

4

28

NervGen Pharma Corp.

@NervgenP

11 days

The CONNECT SCI Study for our Phase 1b/2a clinical trial in #SpinalCordInjury is enrolling subjects. The study involves NVG-291, an investigational treatment that has the potential to enable the nervous system to repair itself. #SCI #ClinicalTrials

0

6

29

NervGen Pharma Corp.

@NervgenP

2 years

Codi Darnell, @NervgenP blogger, interviews @Paralympics skier, Katie Combaluzier, on sit-skiing after a spinal cord injury.

3

26

NervGen Pharma Corp.

@NervgenP

2 years

Torrey Hills Zoom via @YouTube

8

25

NervGen Pharma Corp.

@NervgenP

11 months

VC, PE pioneer John Ruffolo, Founder/MP @MaverixPe joins NervGen’s Board of Directors. News release ➽: @AbilityLab @ruffoloj #spinalcordinjury #clinicaltrials #innovation

0

4

28

NervGen Pharma Corp.

@NervgenP

2 years

NervGen announces Composition Of Matter Patent for NVG-291 granted by the US Patent and Trade Office. Click link to read more! #biotech #research #drugdevelopment #patent

3

27

NervGen Pharma Corp.

@NervgenP

2 months

#NEWS : @DinaBairWGN of @WGNNews spoke with @monicaperezphd from @AbilityLab about our CONNECT SCI Study. #clinicaltrial Learn more about eligibility requirements and enrollment: Read the article: #SCI

1

7

27

NervGen Pharma Corp.

@NervgenP

2 years

Stroke drug from @NervGenP improves memory and repairs injured brain tissue in mice reports @newscientist #Science #ScientificResearch

6

7

27

NervGen Pharma Corp.

@NervgenP

9 months

“I’m a big believer in open-source information as much as possible,” says Nana Collett, VP, program management at @NervgenP . “I understand companies need proprietary information, but I’m a bit radical this way. I believe that as an ecosystem, we’re going to get stronger if we can

0

3

26

NervGen Pharma Corp.

@NervgenP

2 months

NervGen participated in @SCISymposium and our President & CEO, Mike Kelly, spoke with @BrianOrelli of @BiotechTVHQ about the progress of our lead drug candidate, NVG-291, currently being evaluated in a Phase 1b/2a clinical trial.

1

6

26

NervGen Pharma Corp.

@NervgenP

3 years

Paul Brennan, CEO, @NervgenP interviewed by @KevinPriceLive on the company's advances in spinal cord injury treatment. Listen to this nationally syndicated radio interview at link below:

8

7

25

NervGen Pharma Corp.

@NervgenP

2 years

NervGen co-founder interview featured in @Medium 's @AuthorityMag about changing the world through science. #biotech #scienceinthenews #ScienceResearch

2

25

NervGen Pharma Corp.

@NervgenP

3 months

NervGen today announced the results of its Annual General Meeting of Shareholders held on June 4, 2024. Also announced was the appointment of Glenn Ives as Chair of the Board and John Ruffolo as Chair of the Audit Committee. Full release: #announcement

3

2

25

NervGen Pharma Corp.

@NervgenP

1 year

𝐌𝐢𝐤𝐞 𝐊𝐞𝐥𝐥𝐲 @NervgenP CEO who has “moved successfully through smaller biotech’s and commercial launches” on the importance of building and maintaining relationships with CDMO’s in @OutsourcedPharm . #innovation #biotech

0

5

24

NervGen Pharma Corp.

@NervgenP

3 years

Check out the interview with NervGen President & CEO, Paul Brennan, on @MidasLetter ! #spinalcordinjury #multiplesclerosis #alzheimers #research #biotech

Midas Letter

@MidasLetter

3 years

🩻 @NervgenP $NGEN $NGENF has created a groundbreaking new class of #neurorepartive drugs that allow the #nervoussystem to heal itself 🩺 Its leading drug is a clinical-stage candidate for treating spinal cord injuries, #MultipleSclerosis & #Alzheimers

0

2

8

1

6

25

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma and study in Stroke is featured in @newscientist magazine - click link to read more!! #neuroscience #research #biotech #stroke #drugdevelopment

Stroke drug improves memory and repairs injured brain tissue in mice

Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from...

www.newscientist.com

1

3

25

NervGen Pharma Corp.

@NervgenP

1 month

NervGen will be presenting on August 13, 2024, 10 a.m. EDT at the Canaccord Genuity 44th Annual Growth Conference being held August 13-15, 2024, in Boston. The presentation will be webcast with a replay available following the event. Full news release:

0

8

24

NervGen Pharma Corp.

@NervgenP

10 months

@NervgenP (TSX-V: NGEN; OTCQX: NGENF), announced today that renowned neuroscientist, Dr. Jerry Silver, inventor of NervGen’s lead drug candidate, NVG-291, joined @GuyKawasaki on his acclaimed podcast, “Remarkable People.” The full news release is available at the link below:

0

7

24

NervGen Pharma Corp.

@NervgenP

3 years

Did you see the recent article from @BioTuesdays ? Click link below to read about NervGen's history, our technology & how we are unleashing the nervous system to heal itself! #neuroscience #neurorestorative #alzheimers #MultipleSclerosis #spinalcordinjury

NervGen unleashing nervous system to heal itself - BioTuesdays

NervGen Pharma (TSX-V:NGEN; OTCQX:NGENF) is developing a new class of drugs that repairs damage to the nervous system and restores motor, sensory and cognitive function to diseases where there are...

biotuesdays.com

3

6

23

NervGen Pharma Corp.

@NervgenP

1 year

We are delighted to announce the appointment of Mr. Michael Kelly to the position of President & CEO starting April 10, 2023! Read full press release at link below. #newceo #ceo #biotech #management #clinicaltrial #research #neuroscience #spinalcordinjury

4

2

22

NervGen Pharma Corp.

@NervgenP

2 years

Extraordinary preclinical outcomes for stroke treatment with @NervGenP 's injectable compound featured in @HealthEuropa : #Biotechnology #clinicaltrials #stroke

2

5

24

NervGen Pharma Corp.

@NervgenP

2 years

NervGen CEO, Paul Brennan, on how restoring brain plasticity is secret to reversing brain damage in @Tech_Networks

How Restoring Brain Plasticity Is the Secret to Reversing Brain Damage

For the world’s leading neuroscientists, unlocking the brain’s capacity to stimulate neural plasticity has become something of a Holy Grail. In this Insight, NervGen Pharma president and CEO Paul...

www.technologynetworks.com

3

9

23

NervGen Pharma Corp.

@NervgenP

1 year

NervGen Pharma Reports 2022 Year End Results And Provides Operational Update Including Plans To Initiate Phase 1b/2a Clinical Trial Of Proprietary NVG-291 in Q3 2023. Read full press release at link - #drugdevelopment #clinicaltrial #spinalcordinjury

5

0

22

NervGen Pharma Corp.

@NervgenP

2 years

"Unless they live with it, most people... do not know what it is like to experience the fatigue that is a big part of MS." Read more from @MSassociation - #multiplesclerosis #fatigue #blog

What I Wish People Understood About MS Fatigue - MS Conversations

MS fatigue is different for everyone. This blog post shares responses from more than 1,300 people living with MS.

blog.mymsaa.org

3

5

21

NervGen Pharma Corp.

@NervgenP

2 years

Paul Brennan, NervGen Pharma Corp ((TSX-V: NGEN, OTCQX: NGENF) President & CEO, on enabling the nervous system to repair itself in interview with Torrey Hills Capital.

2

22

NervGen Pharma Corp.

@NervgenP

13 days

. @DinaBairWGN of @WGNNews spoke with @monicaperezphd from @AbilityLab about our CONNECT SCI Study. Learn more about eligibility requirements and enrollment here: Read more: #SCI #ClinicalTrials

0

4

22

NervGen Pharma Corp.

@NervgenP

4 months

NervGen today reported its financial results and operational updates for the first quarter of 2024. Read the full release here:

3

4

22

NervGen Pharma Corp.

@NervgenP

14 days

NervGen is presenting on Sep. 10, at 9:30 a.m. EDT, at the H.C. Wainwright 26th Annual Global Investment Conference being held Sep. 9-11, 2024, in New York City, and will be available for 1-on-1 investor meetings at the conference. Full news release:

0

6

22

NervGen Pharma Corp.

@NervgenP

2 years

Why restoring brain plasticity is the secret to restoring brain plasticity in @GritDaily article by @NervgenP CEO

6

2

21

NervGen Pharma Corp.

@NervgenP

2 years

Bill Radvak, @NervgenP co-founder, on advancing medical innovations from battlefield to mainstream medicine for TBI and SCI patients for @GritDaily #spinalcordinjury #TBI

4

5

20

NervGen Pharma Corp.

@NervgenP

19 days

NervGen today reported its financial results and operational updates for the second quarter of 2024. Read the full release here:

0

4

21

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma provides a positive update on the Phase 1 clinical trial at the 14th Annual Meeting of the American Neurological Association, @TheNewANA1 . Click link below to read more! #clinicaltrial #research #biotech #neuroscience #ANA2021

2

7

20

NervGen Pharma Corp.

@NervgenP

11 months

Dr. Harold Punnett, co-founder, @NervgenP on @KevinPriceLive 𝗧𝗵𝗲 𝗣𝗿𝗶𝗰𝗲 𝗼𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀, a nationally syndicated business radio show. 𝐋𝐢𝐧𝐤 𝐭𝐨 𝐛𝐫𝐢𝐞𝐟 + 𝐫𝐚𝐝𝐢𝐨 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰: ⫸ #spinalcordinjury @MaverixPe

0

6

20

NervGen Pharma Corp.

@NervgenP

2 years

Paul Brennan, @NervgenP CEO, talks about its disruptive systemic approach in treating Alzheimer's, and other neurodegenerative diseases, with @yourpodcastguy on @GritDaily podcast! #biotechstartupinnovations #Alzheimers

2

5

19

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma reports 2021 year end results and provides update on Phase 1 study. Click link below to read full press release! #yearend #financialreports #clinicaltrial #research #neuroscience

3

2

20

NervGen Pharma Corp.

@NervgenP

2 years

Read the incredible story of Kathryn Simpson and how she learned to navigate new motherhood in the aftermath of a stroke. #stroke #inspiration #motherhood

Navigating New Motherhood in the Aftermath of a Stroke - NervGen Pharma

By Codi Darnell October 18, 2022 Everyone experiences events that alter the course of their life; many of them are embraced: the chance encounters that turn into long-term partnerships; the arrival...

nervgen.com

2

1

19

NervGen Pharma Corp.

@NervgenP

1 year

Mike Kelly, @NervGenP President & CEO is interviewed in @OutsourcedPharm about the role of intellectual responsibility in drug development. #spinalcordinjury #clinicaltrials #clinicalresearch

0

2

19

NervGen Pharma Corp.

@NervgenP

2 years

NervGen Pharma presenting at the upcoming 2022 American Academy of Neurology Annual Meeting, April 2-7. Read full press release at link below! @AANMember

3

5

19

NervGen Pharma Corp.

@NervgenP

2 years

Wishing you and yours a happy holiday season, from everyone at NervGen! #happyholidays #holidayseason

3

1

19

NervGen Pharma Corp.

@NervgenP

3 years

Learn more about @NervgenP spinal cord trial at @AbilityLab in FREE webinar this Friday at 12 noon ET. Please click the link below to join the webinar on 1/14 at 12 noon ET:

2

5

19

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Director of Research, Marc DePaul, is a keynote speaker at the 10th Annual Neuroscience Virtual Conference hosted by @Labroots on March 10, 2022. Check out the event at link below & register to attend! #LRneuro #neuroscience #keynote #biotech

Neuroscience Virtual Event Series 2022

Labroots is excited to present the 10th annual event in the Neuroscience Virtual Event Series.

www.labroots.com

1

19

NervGen Pharma Corp.

@NervgenP

3 years

NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial. Read full press release at link here - #clinicaltrials #research #biotech #multiplesclerosis #alzheimers #spinalcordinjury #neuroscience

3

0

19